In-vitro activity of fosfomycin against Escherichia coli and Klebsiella pneumoniae bloodstream isolates and frequency of OXA-48, NDM, KPC, VIM, IMP types of carbapenemases in the carbapenem-resistant groups
- PMID: 34495816
- DOI: 10.1080/1120009X.2021.1963618
In-vitro activity of fosfomycin against Escherichia coli and Klebsiella pneumoniae bloodstream isolates and frequency of OXA-48, NDM, KPC, VIM, IMP types of carbapenemases in the carbapenem-resistant groups
Abstract
The aim of this study was to determine the in-vitro activity of fosfomycin against Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) isolates and the frequency of OXA-48, NDM, KPC, VIM, IMP types of carbapenemases in the carbapenem-resistant (CR) groups. A total of 346 isolates (126 E. coli and 220 K. pneumoniae) from nosocomial bloodstream infections were included. Carbapenem and fosfomycin susceptibility were tested by Etest (bioMerieux, France) and agar dilution methods, respectively and evaluated in accordance with EUCAST criteria. The presence of OXA-48, NDM, KPC, VIM, IMP types of carbapenemases were conducted by using PCR method. Of the total 346 isolates, 185 (41 E. coli, 144 K. pneumoniae) were CR. Fosfomycin susceptibility of E. coli was higher than 95% and was not statistically significant between the CR and carbapenem-susceptible (CS) groups. Fosfomycin susceptibility of CS and CR K. pneumoniae was 90.7% and 69.4%, respectively, and statistically significantly lower in CR group. Of the total 185 CR isolates, 163 (32 E. coli, 131 K. pneumoniae) were producing carbapenemases. OXA-48 was the prominent carbapenemase type produced by E. coli (96.8%) and K. pneumoniae (70.9%). The frequency of NDM and KPC types produced by K. pneumoniae was 20.6% and 15.2%, respectively. Fosfomycin has substantial in-vitro activity against nosocomial CS and CR E. coli and CS K. pneumoniae bloodstream isolates. However, due to the risk of emerging resistance with fosfomycin monotherapy, combination therapy should be considered to obtain the possible additive or synergistic activity. Emerging fosfomycin resistance of CR K. pneumoniae isolates is alarming and OXA-48 is still the prominent carbapenemase type in Turkey.
Keywords: Fosfomycin resistance; bloodstream infection; carbapenem resistance; OXA-48; NDM; KPC; VIM; IMP.
Similar articles
-
[Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].Mikrobiyol Bul. 2016 Jan;50(1):21-33. doi: 10.5578/mb.10695. Mikrobiyol Bul. 2016. PMID: 27058326 Turkish.
-
Multicentre investigation of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing K. pneumoniae.Infect Genet Evol. 2019 Apr;69:61-67. doi: 10.1016/j.meegid.2019.01.013. Epub 2019 Jan 14. Infect Genet Evol. 2019. PMID: 30654179
-
[Comparison of the modified Hodge test and the Carba NP test for detection of carbapenemases in Enterobacteriaceae isolates].Mikrobiyol Bul. 2016 Jan;50(1):1-10. doi: 10.5578/mb.10861. Mikrobiyol Bul. 2016. PMID: 27058324 Turkish.
-
Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria.Infect Dis Ther. 2021 Mar;10(1):75-92. doi: 10.1007/s40121-020-00395-2. Epub 2021 Jan 25. Infect Dis Ther. 2021. PMID: 33492641 Free PMC article. Review.
-
Rapidly spreading Enterobacterales with OXA-48-like carbapenemases.J Clin Microbiol. 2025 Feb 19;63(2):e0151524. doi: 10.1128/jcm.01515-24. Epub 2025 Jan 6. J Clin Microbiol. 2025. PMID: 39760498 Free PMC article. Review.
Cited by
-
In Vitro Activity of "Old" and "New" Antimicrobials against the Klebsiella pneumoniae Complex.Antibiotics (Basel). 2024 Jan 26;13(2):126. doi: 10.3390/antibiotics13020126. Antibiotics (Basel). 2024. PMID: 38391512 Free PMC article.
-
Extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches.Transpl Infect Dis. 2022 Aug;24(4):e13881. doi: 10.1111/tid.13881. Epub 2022 Jun 28. Transpl Infect Dis. 2022. PMID: 35691028 Free PMC article. Review.
-
In vitro Antibacterial Effect of Reduning Combined with Polymyxin on Carbapenem Resistant Klebsiella pneumoniae.Infect Drug Resist. 2025 Jan 13;18:227-237. doi: 10.2147/IDR.S490029. eCollection 2025. Infect Drug Resist. 2025. PMID: 39830033 Free PMC article.
-
Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.J Antimicrob Chemother. 2022 Apr 27;77(5):1324-1333. doi: 10.1093/jac/dkac045. J Antimicrob Chemother. 2022. PMID: 35211736 Free PMC article.
-
Ertapenem plus meropenem combination treatment in carbapenem-resistant Klebsiella pneumoniae bacteremia: an analysis of 53 cases.Eur J Clin Microbiol Infect Dis. 2023 Oct;42(10):1269-1273. doi: 10.1007/s10096-023-04660-3. Epub 2023 Sep 7. Eur J Clin Microbiol Infect Dis. 2023. PMID: 37676420
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous